You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Our news

Nevrargenics wins the award of the Project of the Year for Ellorarxine

Nevrargenics Wins "Project of the Year" at the 2025 Bionow Annual Awards

Nevrargenics is proud to announce that our lead programme, Ellorarxine™, has been named Project of the Year at the prestigious 2025 Bionow Annual Awards. The award, presented at the Concorde Conference Centre in Manchester, recognises the most innovative and impactful life sciences projects in the UK. The judges highlighted Nevrargenics’ "major step forward" in neurodegenerative research, specifically our novel RARβ-modulator approach to treating Motor Neurone Disease (MND/ALS).

NHS Suspension Highlights Need for Targeted Therapies

NHS Halts Repurposing Scheme: A Needed Shift

We welcome NHS England’s decision to suspend the national medicines repurposing programme. Neurodegenerative diseases demand purpose-built, innovative treatments, not recycled drugs, to address their complex biology and the vast unmet patient need.

New Publication Highlights RAR Modulator Breakthrough

Publication Highlights RAR Modulator Breakthrough

Nevrargenics announces a new peer-reviewed publication in the American Chemical Society's journal Omega, highlighting the unique mechanism of its next-generation RAR modulators and their promise in tackling neurodegenerative diseases like ALS and Alzheimer’s.

Series of articles on clinical trials

A series of articles on clinical trials published.

Our Chief Medical Officer, Dr Tony Lockett, has published a series of articles on clinical trials setting out his ideas about new approaches to trial design and ethics. The links allow to view and download the articles until June 17, 2025.

Ellorarxine publication in IJMS as part of the Special Issue From Molecules to Medicines: Exploring Neurodegenerative Pathways for Targeted Neuropharmacology

Article on Ellorarxine published in IJMS

A new article was published in the special issue of the International Journal of Molecular Sciences, on the potential therapeutic application of Ellorarxine for the treatment of neurodegenerative disorders.

Our approach in drug discovery and development

Detailed explanation of our drug discovery and development approach

Nevrargenics is pleased to have prepared an outline explaining the company's approach in developing our drugs, with specific focus on Ellorarxine™ for Motor Neuron Disease (MND or ALS). This can be found here: Link

Podcast hosted by The Mark Sommerville Foundation.

Podcast hosted by The Mark Sommerville Foundation

Nevrargenics' CEO, Prof ANdy Whiting and Chief Medical Officer, Dr Tony Lockett, giving an interview at the Podcast of The Mark Sommerville Foundation for Motor Neuron Disease.

Promising results from potential MND treatment study

Article in Neuro Rehab Times

The Neuro Rehab Times ("NR Times"), published an article on Nebvargenics' lead drug candidate with the title "A pioneering study has revealed promising results for a new treatment targeting motor neurone disease (MND)".

Researchers in Durham University's Chemistry department collaborating on the breakthrough MND drug, Ellorarxine, offering hope for neuroprotection, neuroplasticity, and neurorepair in motor neurone disease patients.

Durham Article Highlights Breakthrough MND Treatment

Durham University publishes new findings on Ellorarxine™, Nevrargenics' breakthrough drug for Motor Neurone Disease, highlighting its potential for neuroprotection, neuroplasticity, and neurorepair in combating MND.

Human neurons grown in culture, labeled for proteins MAP2 and GAP43, showing neuroprotective effects of Ellorarxine in neurodegenerative disease models.

Pharmaceutical Manufacturer Publishes Ellorarxine news

A new Pharmaceutical Manufacturer article highlights the neuroprotective effects of Ellorarxine™ in disease models, supporting its development for ALS and MHRA advice for upcoming human trials.

Biogen/Eisai’s Alzheimer’s drug approved by MHRA but not recommended by NICE

Reflections on Recent Developments in Alzheimer's Treatments

As a company dedicated to the fight against neurodegeneration, we at Nevrargenics commend all efforts that push the boundaries of treatment for these devastating diseases.

Bionow Neuroscience Conference, July 2024

Bionow Neuroscience Conference, Sheffield

Bionow Neuroscience Conference, Sheffield, 17th July 2024. Our CEO, Prof Andy Whiting, presented the potential role that Nevrargenics might play in developing truly disease modifying drugs.

Nevrargenics at London County Hall Investor Event

Nevrargenics at London County Hall Investor Event

Nevrargenics proudly participated at a prestigious event in London, right across from the Big Ben and next to St Thomas's Hospital. The event brought together a dynamic group of investors.

Analyst Note published by Edison

Analyst Note published by Edison

Latest overview by Arron Aatkar, healthcare analyst at Edison Group, the leading content-led investor relations business.

MHRA concluded that the preclinical and protocol design was sufficient for the Clinical Trial Application (CTA) submission

Scientific Advice Meeting with the MHRA

The Scientific Advice meeting with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) was held to discuss Nevrargenics’ Motor Neurone Disease drug candidate, NVG0645.

Article published by Research Features - Neuroprotection, neuroplasticity, and neurorepair

Article published by Research Features

Research Features published an article on us entitled "Nevrargenics: Neuroprotection, neuroplasticity, and neurorepair" about the background to, and summary of, our drug development programme.

Nevrargenics participates in BIO Europe

Nevrargenics participates in Bio Europe

We were delighted to take part in Bio Europe Spring 2023 in Basel, Switzerland and have over 30 one-to-one meetings with pharmaceutical companies for potential deals.

Discussing the collaboration between them, the unmet needs for Parkinson's disease and the potential of the novel drugs from Nevrargenics

Interview with Prof. Susan Duty, PhD, FBPhS

Prof Andy Whiting in an interview with Prof. Susan Duty, PhD, FBPhS, from King's College London on Parkinson's.

Treatment Research Initiative to Cure ALS meeting 2022

Treatment Research Initiative to Cure ALS

Nevrargenics participates in the first TRICALS workshop at Schiphol, Netherlands, on ALS since the COVID pandemic.

Initiation of efficacy studies inamyotrophic lateral sclerosis

Iniation of efficacy studies on MS and ALS

Nevrargenics launches efficacy studies on MS and ALS models through Experimentica and Charles River respectively.

CEO interview beyond biotech podcast

Interview of our CEO on Beyond Biotech podcast

CEO Andy Whiting gives an interview to Liza Laws, Senior Editor of Labiotech about neurodegeneration and Nevrargenics's drugs.

Kings College collaboration Parkinson's

Collaboration with King’s College in Parkinson’s

Research collaboration launch with Professor Susan Duty at King’s College, looking the application of our drugs in Parkinson’s disease models.

Mandale Park, Durham

Nevrargenics own premises

Nevrargenics acquires its own premises for the development of its offices and laboratories on Mandale Park in Durham.

Safety studies neuroscience CNS

Lead drug candidate safety studies of completed

Two (once weekly and twice weekly dosing), 28 day tox studies were completed on NVG0645 showing a potential therapeutic window.

neuroprotection in a model of Parkinson’s disease

Nevrargenics drug candidate provides neuroprotection in Parkinson’s model

Nevrargenics reports that lead drug candidate provides neuroprotection in a 6-hydroxydopamine model of Parkinson’s disease.

Neuro-restorative and protective effects of drug NVG0645

Neuro-restorative and protective effects of drug NVG0645 presented

Nevrargenics reports multi-neuro-restorative and protective effects using lead drug as a new therapeutic strategy for ALS.